Leadership structure updates at Anavex Life Sciences involved the appointment of Dr. Terrie Kellmeyer as Interim Chief Executive Officer following the departure of former President and Chief Executive Officer Dr. Christopher Missling. Dr. Kellmeyer brings decades of extensive pharmaceutical development experience to the role, having previously served as the company's Senior Vice President of Clinical Development and holding a background spanning global regulatory affairs, clinical operations, safety, and medical quality assurance. The Board of Directors appointed her to steer the next phase of corporate growth and manage interactions with major regulatory bodies like the FDA and the EMA regarding their central nervous system portfolio. Her leadership focuses heavily on advancing core clinical trials while maintaining financial discipline and a solid operational cash runway.